Gene Cartwright - Guided Therapeutics CEO and President Acting CFO and Director
| GTHP Stock | USD 0.19 0.03 18.75% |
CEO
Dr. Gene Cartwright, Ph.D. is Chief Executive Officer, Acting Chief Financial Officer, President and Director of the company. He was elected as a director on January 31, 2014. His most recent position was with Omnyx, LLC, a Joint Venture between GE Healthcare and the University of Pittsburgh Medical Center, where, as CEO for over four years he founded and managed the successful development of products for the field of Digital Pathology. Prior to his work with Omnyx, LLC, he was President of Molecular Diagnostics for GE Healthcare. Prior to GE, Dr. Cartwright was Divisional Vice PresidentGeneral Manager for Abbott Diagnostics Molecular Diagnostics business. In his 24 year career at Abbott, he also served as Divisional Vice President for U.S. Marketing for five years. He received a Masters of Management degree from Northwesterns Kellogg School of Management and also holds a Ph.D. in chemistry from Stanford University and an AB from Dartmouth College. since 2014.
| Age | 69 |
| Tenure | 10 years |
| Phone | 770 242 8723 |
| Web | https://www.guidedinc.com |
Guided Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6278) % which means that it has lost $0.6278 on every $100 spent on assets. This is way below average. Guided Therapeutics' management efficiency ratios could be used to measure how well Guided Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CEO Age | ||
| Andrew Astor | Nephros | 67 | |
| Robert Banks | Nephros | 49 | |
| Daron Evans | Nephros | 50 | |
Management Performance
| Return On Asset | -0.63 |
Guided Therapeutics Leadership Team
Elected by the shareholders, the Guided Therapeutics' board of directors comprises two types of representatives: Guided Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guided. The board's role is to monitor Guided Therapeutics' management team and ensure that shareholders' interests are well served. Guided Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guided Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gene Cartwright, CEO and President Acting CFO and Director | ||
| Mark Faupel, Chief Scientific Officer |
Guided Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Guided Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.63 | |||
| Operating Margin | (38.63) % | |||
| Current Valuation | 19.66 M | |||
| Shares Outstanding | 48.58 M | |||
| Shares Owned By Insiders | 39.69 % | |||
| Shares Owned By Institutions | 12.65 % | |||
| Price To Earning | 36.67 X | |||
| Price To Sales | 219.47 X | |||
| Revenue | 81 K | |||
| Gross Profit | 20 K |
Pair Trading with Guided Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Guided Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Guided Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Guided OTC Stock
| 0.48 | SEMHF | Siemens Healthineers | PairCorr |
| 0.44 | SMMNY | Siemens Healthineers | PairCorr |
| 0.44 | PHG | Koninklijke Philips | PairCorr |
| 0.42 | SCTSF | Scottie Resources Corp | PairCorr |
The ability to find closely correlated positions to Guided Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Guided Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Guided Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Guided Therapeutics to buy it.
The correlation of Guided Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Guided Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Guided Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Guided Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.